Cannabis Bonanza by Ziv Genesove

After years of conservatism and “Reefer Madness” style propaganda, the Israeli “Anti Drug Authority” had surprisingly decided to support decriminalization of all drugs. The Minister of Internal Security is strongly against the idea, but many Israelis feel now they finally have a chance to change the drug policy in the country – and they aren’t going to let this opportunity go to waste.

Medical cannabis for the treatment of chronic pain and other disorders: misconceptions and facts

Recently, many countries have enacted new cannabis policies, including decriminalization of cannabis possession, medical cannabislegalization, and legalization of recreational cannabis.  In this context, patients and their physicians have had an increasing number of conversations about the risks and benefits of cannabis.  While cannabis and cannabinoids continue to be evaluated as pharmacotherapy for medical conditions, currently, the best evidence exists for the following medical conditions: chronic pain, neuropathic pain, and spasticity resulting from multiple sclerosis.

Prevalence and motives for drugged driving among emerging adults presenting to an emergency department

Drugged driving [DD] is a public health concern, particularly among emerging adults who have the highest rates of drug use. Understanding involvement with DD could inform prevention efforts for this population. We evaluated the prevalence of, motives for, and correlates of past-year DD among emerging adults from an urban, under-resourced community.

Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study

Current levels and dangers of opioid use in the U.S. warrant the investigation of harm-reducing treatment alternatives. The clinically and statistically significant evidence of an association between medical cannabis programme enrollment and opioid prescription cessation and reductions and improved quality of life warrants further investigations on cannabis as a potential alternative to prescription opioids for treating chronic pain.

Review: The Role of Cannabinoids on Esophageal Function-What We Know Thus Far

The endocannabinoid system (ECS) primarily consists of cannabinoid receptors (CBRs), endogenous ligands, and enzymes for endocannabinoid biosynthesis and inactivation. Given the varying and sometimes limited efficacy of current medical therapies for diseases of the esophagus, further understanding and investigation into the interplay of the ECS on esophageal health and disease may present new therapeutic modalities that may help advance current treatment options.

Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation

Cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) have well documented immunomodulatory effects in vitro, but not following oral administration in humans. Immune cells from MS patients were more susceptible to the immunosuppressive effects of cannabinoids than those from healthy volunteers or cancer patients. Administering cannabinoids with a high-fat meal or in lipid-based formulations has the potential to be a therapeutic approach to improve the treatment of MS, or indeed other autoimmune disorders.

Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation

There is considerable public and political interest in the use of cannabis products for medical purposes. The task force of the European Pain Federation (EFIC) conducted a survey with its national chapters representatives on the status of approval of all types of cannabis-based medicines, the covering of costs and the availability of a position paper of a national medical association on the use of medical cannabis for chronic pain and for symptom control in palliative/supportive care.